Back to News
Market Impact: 0.25

Benjamin Graham Detailed Fundamental Analysis

ISRGNDAQ
Company FundamentalsAnalyst InsightsCorporate EarningsHealthcare & Biotech
Benjamin Graham Detailed Fundamental Analysis

Validea's guru fundamental report rates Intuitive Surgical (ISRG), a large-cap medical equipment stock, at 71% using its Benjamin Graham-based Value Investor model. While ISRG passes several fundamental criteria, including sales, current ratio, debt, and long-term EPS growth, it notably fails the low P/E and P/B ratio tests, which are central to Graham's deep value methodology. This indicates that despite strong operational fundamentals, ISRG's current valuation metrics do not fully align with a classic deep value investment profile according to this specific strategy, falling below the 80% threshold for 'some interest'.

Analysis

Intuitive Surgical (ISRG) presents a classic case of a high-quality growth company failing to meet the stringent criteria of a deep value investment screen. According to a Validea report using Benjamin Graham's methodology, ISRG scores 71%, which is below the 80% threshold considered necessary for investment interest under this model. The analysis reveals a significant dichotomy: ISRG exhibits strong operational fundamentals, passing tests for sales, current ratio, long-term EPS growth, and maintaining low long-term debt relative to net current assets. However, it explicitly fails on the two core valuation metrics central to the Graham strategy: its Price-to-Earnings (P/E) and Price-to-Book (P/B) ratios are too high. This indicates that while the company is fundamentally sound and growing, its current market price reflects a premium valuation that is inconsistent with the principles of deep value investing.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

mixed

Sentiment Score

0.00

Ticker Sentiment

ISRG0.20
NDAQ0.00

Key Decisions for Investors

  • Strict value investors following a Graham-style approach should view ISRG with caution, as its high P/E and P/B ratios disqualify it as a classic value opportunity despite its strong underlying fundamentals.
  • Growth-oriented investors may find the positive signals in sales, long-term EPS growth, and balance sheet health compelling, but must be prepared to justify the premium valuation that caused the stock to fail the value screen.
  • The 71% score serves as a quantitative flag of the conflict between ISRG's operational quality and its market valuation, suggesting investors should assess if their strategy prioritizes fundamental strength or valuation discipline.